|
Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Exelixis; Ipsen |
|
|
Consulting or Advisory Role - Outcomes4Me |
|
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Takeda |
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst) |
|
|
Research Funding - Merck Sharp & Dohme (Inst); Nestle health science (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Conjupro Biotherapeutics; Exelixis; Purdue Pharma |
Research Funding - Acetylon Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst) |
Travel, Accommodations, Expenses - Exelixis |
|
|
|
Honoraria - Alaunus Global; Clinical Care Options; Leerink; Merck; MI Bioresearch; PRMA Consulting |
Consulting or Advisory Role - Alcimed; Celgene; Defined Health; Five Prime Therapeutics; Gfk; Merck; PureTech; Putnam Associates |
Research Funding - Amgen (Inst); Merck |
Travel, Accommodations, Expenses - Clinical Care Options; Genentech; Merck; PRMA Consulting; PureTech |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb |
Research Funding - Merck; Tesaro |
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; BiolineRx |
Consulting or Advisory Role - AstraZeneca; Genentech; Merck; Nanobiotix |
Travel, Accommodations, Expenses - Nanobiotix |
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Perkin Elmer |
Consulting or Advisory Role - AstraZeneca; Perkin Elmer |
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead company; Merck |
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use. |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche |
|
|
Employment - Dana-Farber Cancer Institute |
Stock and Other Ownership Interests - Apricity Health |
Consulting or Advisory Role - Aduro Biotech; Amgen; Bayer; Bristol-Myers Squibb; Celldex; EMD Serono; Genentech/Roche; Incyte; Incyte; Incyte; Merck Sharp & Dohme; Novartis; Pfizer; Sanofi; Verastem |
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst) |
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis |
Other Relationship - Bristol-Myers Squibb; Genentech/Roche |
|
Jonathan Daniel Schoenfeld |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group; Nanobiotix; Tilos Therapeutics |
Research Funding - Bristol-Myers Squibb; Merck |